JP2018513687A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513687A5 JP2018513687A5 JP2017553189A JP2017553189A JP2018513687A5 JP 2018513687 A5 JP2018513687 A5 JP 2018513687A5 JP 2017553189 A JP2017553189 A JP 2017553189A JP 2017553189 A JP2017553189 A JP 2017553189A JP 2018513687 A5 JP2018513687 A5 JP 2018513687A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- cells
- cell
- car
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 114
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 43
- 102000001301 EGF receptor Human genes 0.000 claims description 37
- 108060006698 EGF receptor Proteins 0.000 claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 210000000130 stem cell Anatomy 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 208000026310 Breast neoplasm Diseases 0.000 claims description 12
- 230000000139 costimulatory effect Effects 0.000 claims description 12
- 208000005017 glioblastoma Diseases 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 10
- 206010027476 Metastases Diseases 0.000 claims description 10
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 10
- 230000009401 metastasis Effects 0.000 claims description 10
- 230000000174 oncolytic effect Effects 0.000 claims description 9
- 241000283690 Bos taurus Species 0.000 claims description 8
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 8
- 241000700584 Simplexvirus Species 0.000 claims description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 241000699670 Mus sp. Species 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 241000282472 Canis lupus familiaris Species 0.000 claims description 4
- 241000283086 Equidae Species 0.000 claims description 4
- 241000282326 Felis catus Species 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 206010059282 Metastases to central nervous system Diseases 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 241000282465 Canis Species 0.000 description 4
- 241000283073 Equus caballus Species 0.000 description 4
- 241000282324 Felis Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562143744P | 2015-04-06 | 2015-04-06 | |
| US62/143,744 | 2015-04-06 | ||
| PCT/US2016/026057 WO2016164370A1 (en) | 2015-04-06 | 2016-04-05 | Egfr-directed car therapy for glioblastoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020115454A Division JP2020156522A (ja) | 2015-04-06 | 2020-07-03 | 神経膠芽腫のためのｅｇｆｒ指向ｃａｒ療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513687A JP2018513687A (ja) | 2018-05-31 |
| JP2018513687A5 true JP2018513687A5 (enExample) | 2019-05-16 |
| JP6879932B2 JP6879932B2 (ja) | 2021-06-02 |
Family
ID=57073323
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017553189A Expired - Fee Related JP6879932B2 (ja) | 2015-04-06 | 2016-04-05 | 神経膠芽腫のためのｅｇｆｒ指向ｃａｒ療法 |
| JP2020115454A Pending JP2020156522A (ja) | 2015-04-06 | 2020-07-03 | 神経膠芽腫のためのｅｇｆｒ指向ｃａｒ療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020115454A Pending JP2020156522A (ja) | 2015-04-06 | 2020-07-03 | 神経膠芽腫のためのｅｇｆｒ指向ｃａｒ療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11045543B2 (enExample) |
| EP (1) | EP3280437A4 (enExample) |
| JP (2) | JP6879932B2 (enExample) |
| KR (1) | KR20180012749A (enExample) |
| CN (1) | CN108367057B (enExample) |
| AU (1) | AU2016246457B2 (enExample) |
| CA (1) | CA2981979A1 (enExample) |
| HK (1) | HK1250918A1 (enExample) |
| WO (1) | WO2016164370A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015259877B2 (en) | 2014-05-15 | 2021-02-25 | National University Of Singapore | Modified natural killer cells and uses thereof |
| PL3362470T3 (pl) * | 2015-10-13 | 2022-02-21 | City Of Hope | Chimeryczne receptory antygenowe zawierające domenę chlorotoksyny |
| CN108261426B (zh) * | 2017-01-04 | 2019-04-05 | 杭州康万达医药科技有限公司 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| CN107354199A (zh) * | 2017-07-04 | 2017-11-17 | 武汉波睿达生物科技有限公司 | 一种检测靶向cd30的cart细胞中car表达的荧光定量试剂盒 |
| CN107759701B (zh) * | 2017-10-27 | 2021-07-02 | 杭州优善生物科技有限公司 | 嵌合抗原受体、其修饰的NK细胞、编码DNA、mRNA、表达载体、制备方法和应用 |
| CN109836497A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向egfr的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| CN108315305B (zh) * | 2017-12-26 | 2020-11-06 | 沣潮医药科技（上海）有限公司 | 携带嵌合抗原受体的免疫细胞外泌体的制备方法及其应用 |
| AU2019219454A1 (en) | 2018-02-09 | 2020-08-27 | National University Of Singapore | Activating chimeric receptors and uses thereof in natural killer cell immunotherapy |
| SG11202008976YA (en) | 2018-04-02 | 2020-10-29 | Nat Univ Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| CN109568351B (zh) * | 2018-11-30 | 2020-02-21 | 武汉波睿达生物科技有限公司 | 溶瘤病毒和car-t联合应用针对实体肿瘤的治疗 |
| CN111378046B (zh) * | 2018-12-27 | 2024-03-15 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞转换受体 |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| CN110592024A (zh) * | 2019-09-12 | 2019-12-20 | 广东食品药品职业学院 | 以tEGFR与CD19为双靶点的CAR-NK细胞制备方法及其应用 |
| CN110845623B (zh) * | 2019-10-11 | 2021-07-09 | 厦门大学 | 一种egfr特异性嵌合抗原受体及其应用 |
| JP7727326B6 (ja) * | 2020-01-19 | 2025-09-08 | 北京▲峠▼替医療技術有限公司 | 免疫細胞の機能を向上させる強化受容体 |
| WO2021150936A1 (en) * | 2020-01-22 | 2021-07-29 | City Of Hope | Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer |
| CN111925448B (zh) * | 2020-08-03 | 2022-06-21 | 山东大学 | 在体生成car-巨噬细胞的制备方法及肿瘤免疫治疗中的应用 |
| MX2023002887A (es) * | 2020-09-10 | 2023-08-16 | Mustang Bio Inc | Terapia combinada que comprende células t del receptor de antígenos quiméricos (car) dirigidas al cáncer y un método para utilizar las mismas para un tratamiento para el cáncer. |
| WO2022068870A1 (zh) * | 2020-09-30 | 2022-04-07 | 中国科学院动物研究所 | 靶向egfr的嵌合抗原受体 |
| WO2023034758A1 (en) * | 2021-08-30 | 2023-03-09 | Cytoimmune Therapeutics, Inc. | Methods and compositions for cell expansion |
| WO2024151777A1 (en) * | 2023-01-11 | 2024-07-18 | The Trustees Of The University Of Pennsylvania | Hydrogels for intratumoral delivery of cellular immunotherapies |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL151873A0 (en) | 2000-03-24 | 2003-04-10 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| CA2479763A1 (en) * | 2002-03-27 | 2003-10-09 | Baylor College Of Medicine | Potent oncolytic herpes simplex virus for cancer therapy |
| JP3803790B2 (ja) * | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | 新規なダイアボディ型二重特異性抗体 |
| JP2005333993A (ja) * | 2005-08-03 | 2005-12-08 | Tohoku Techno Arch Co Ltd | 新規なダイアボディ型二重特異性抗体 |
| US20110052570A1 (en) * | 2005-10-26 | 2011-03-03 | Children's Medical Center Corporation | Method to prognose response to anti-egfr therapeutics |
| EP2418223A3 (en) | 2006-06-12 | 2013-01-16 | Emergent Product Development Seattle, LLC | Single-chain multivalent binding proteins with effector function |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| US8822647B2 (en) | 2008-08-26 | 2014-09-02 | City Of Hope | Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells |
| ES2656414T3 (es) | 2010-09-08 | 2018-02-27 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| ES2872077T3 (es) * | 2011-04-08 | 2021-11-02 | Us Health | Receptor de antígenos quiméricos anti-variante III del receptor de factor de crecimiento epidérmico y uso de los mismos para el tratamiento de cáncer |
| CA2843158A1 (en) | 2011-08-26 | 2013-03-07 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
| JP6053688B2 (ja) | 2011-10-07 | 2016-12-27 | 国立大学法人三重大学 | キメラ抗原受容体 |
| CN104168922A (zh) | 2011-11-16 | 2014-11-26 | 安姆根有限公司 | 治疗表皮生长因子缺失突变体viii相关疾病的方法 |
| EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| CA3205751A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| CN103483452B (zh) * | 2012-06-12 | 2021-08-13 | 上海细胞治疗集团有限公司 | 双信号独立的嵌合抗原受体及其用途 |
| CN103113470B (zh) * | 2013-02-27 | 2015-04-22 | 四川大学 | 靶向人egfr的基因工程化淋巴细胞及其制备方法和用途 |
| WO2014138704A1 (en) * | 2013-03-07 | 2014-09-12 | Baylor College Of Medicine | Targeting cd138 in cancer |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| AU2014259675B2 (en) * | 2013-05-03 | 2019-05-02 | Ohio State Innovation Foundation | CS1-specific chimeric antigen receptor engineered immune effector cells |
| US9517276B2 (en) * | 2013-06-04 | 2016-12-13 | Cytomx Therapeutics, Inc. | Compositions and methods for conjugating activatable antibodies |
| AU2014337367B2 (en) | 2013-10-15 | 2020-04-30 | The Scripps Research Institute | Peptidic chimeric antigen receptor T cell switches and uses thereof |
| EP3831398A1 (en) | 2013-10-25 | 2021-06-09 | PsiOxus Therapeutics Limited | Oncolytic adenoviruses armed with heterologous genes |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| JP7054622B2 (ja) | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| US10973914B2 (en) | 2015-02-20 | 2021-04-13 | Ohio State Innovation Foundation | Bivalent antibody directed against NKG2D and tumor associated antigens |
| EP3270937A4 (en) | 2015-03-26 | 2018-09-12 | The Trustees Of Dartmouth College | Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using |
| MA44314A (fr) | 2015-11-05 | 2018-09-12 | Juno Therapeutics Inc | Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées |
| EP3504245A4 (en) | 2016-08-23 | 2020-04-22 | The Regents of The University of California | PROTEOLYTICLY CLEAVABLE CHIMERAL POLYPEPTIDES AND METHOD FOR USE THEREOF |
-
2016
- 2016-04-05 JP JP2017553189A patent/JP6879932B2/ja not_active Expired - Fee Related
- 2016-04-05 WO PCT/US2016/026057 patent/WO2016164370A1/en not_active Ceased
- 2016-04-05 HK HK18110330.8A patent/HK1250918A1/zh unknown
- 2016-04-05 CN CN201680025143.5A patent/CN108367057B/zh not_active Expired - Fee Related
- 2016-04-05 KR KR1020177031930A patent/KR20180012749A/ko not_active Ceased
- 2016-04-05 AU AU2016246457A patent/AU2016246457B2/en not_active Ceased
- 2016-04-05 US US15/564,166 patent/US11045543B2/en not_active Expired - Fee Related
- 2016-04-05 EP EP16777143.5A patent/EP3280437A4/en not_active Withdrawn
- 2016-04-05 CA CA2981979A patent/CA2981979A1/en active Pending
-
2020
- 2020-07-03 JP JP2020115454A patent/JP2020156522A/ja active Pending
-
2021
- 2021-03-12 US US17/200,322 patent/US20210308261A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513687A5 (enExample) | ||
| US12053491B2 (en) | Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20 | |
| US20210130432A1 (en) | Anti-human papillomavirus 16 e7 t cell receptors | |
| RU2751236C2 (ru) | КОНСТРУИРОВАНИЕ ОБЛИГАТНОГО ВЕКТОРА НА ОСНОВЕ ОНКОЛИТИЧЕСКИХ ВИРУСОВ ПРОСТОГО ГЕРПЕСА (oHSV) И КОНСТРУКЦИИ ДЛЯ ТЕРАПИИ РАКА | |
| JP2021036887A (ja) | ヒト化抗ｏｘ４０抗体及びその使用 | |
| JP2018518152A5 (enExample) | ||
| US20230071098A1 (en) | Anti-gpc3 single-chain antibody-containing car | |
| CN105452288A (zh) | 抗人乳头瘤病毒16 e6 t细胞受体 | |
| RU2014118555A (ru) | Химерные антигенные рецепторы к cd22 | |
| JP2013541335A5 (enExample) | ||
| US20230346835A1 (en) | Chimeric antigen receptor targeting bcma and use thereof | |
| CN107109369B (zh) | 用于富集具有外源性免疫受体的工程化t细胞的抗体的用途和用于清除工程化t细胞的抗体 | |
| JP2024501888A (ja) | Ｂｃｍａに特異的に結合する抗体およびその使用 | |
| WO2021190550A1 (zh) | 含有保护肽的嵌合抗原受体及其用途 | |
| AU2015346350A1 (en) | Anti-thyroglobulin t cell receptors | |
| CN114195882A (zh) | Tcr及其用途 | |
| JPWO2021195536A5 (enExample) | ||
| RU2839662C1 (ru) | Т-клетки с двумя химерными антигенными рецепторами car | |
| HK40115184A (en) | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 | |
| JP2025542097A (ja) | 抗ａｆｐ／ｈｌａ０２ ｔｃｒ様抗体及びその使用 | |
| CN120590509A (zh) | 分离的特异性结合MHC/Survivin表位复合体的肿瘤特异性TCR及其用途 | |
| CN116284409A (zh) | Gpc3 car-t细胞及其在制备治疗癌症的药物中的用途 | |
| RU2021134337A (ru) | Устойчивые к ритуксимабу химерные антигенные рецепторы и пути их применения | |
| Calmels et al. | Secretomers as a new tool for the monitoring of CTL responses | |
| HK40001773A (en) | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |